
Revolax Sub-Q Lidocaine 1,1ml
45,00 €
Add to cartRevolax Sub-Q Lidocaine 1,1ml
45,00 €
-
Delivery Return
Delivery
Products are shipped within the European Union.
Delivery time: 1 to 7 business days depending on the destination country.
Delivery options and costs are displayed during checkout.Return
Customers have the right to complain about defective products.
Complaints should be submitted via e-mail to: info@aestheticmedicine.shop
Complaints are reviewed within 14 business days.Help
- Give us a shout if you have any other questions and/or concerns.
- Email: info@aestheticmedicine.shop
-
Ask a Question
Ask a Question
Revolax Sub-Q Lidocaine 1,1ml
45,00 €If this description is not sufficient, please send us a question to this product. We will reply as soon as possible.

Free
Shipping in Europe
for orders over 1000 €
100%
Guaranteed
Satisfaction
Safe
Stripe
Payments
REVOLAX Sub-Q contains high-purity hyaluronic acid of non-animal origin, which is a 100% natural substance that optimally synchronizes with human skin tissues. The product is completely purified of the BDDE cross-linking agent, which ensures a high level of safety for the patient.
The extraordinary technology of REVOLAX cross-linked hyaluronic acid has been contained in the form of a thick and durable gel. High viscoelasticity is one of the distinguishing features of REVOLAX. This plastic consistency allows for the creation of instant and lasting volume, and furthermore allows the product to be distributed evenly with a natural finish.
Intended use:
- volumetry and face contouring – nose correction, cheek filling and modeling of cheekbones and chin,
- filling deep wrinkles.
Effect persistence:
- 8-12 months
Composition:
- Cross-linked hyaluronic acid 20mg/ml
- lidocaine 3mg/ml
The package contains:
- 1x 1 ml pre-filled syringe.
Product for use by professionals only.
By deciding to purchase, you declare that you are a doctor or cosmetologist trained in the field of aesthetic medicine
You must be logged in to post a review.
Reviews
There are no reviews yet.